Galectin Therapeutics (GALT) Income from Continuing Operations (2010 - 2026)
Galectin Therapeutics' (GALT) quarterly Income from Continuing Operations came in at 6029000.0 in Q1 2026, up 37.24% year-on-year from 4393125.54 in Q1 2025, and down 14.21% quarter-over-quarter from 5279000.0 in Q4 2025.
Galectin Therapeutics (GALT) Income from Continuing Operations (2010 - 2026) Analysis & Trends
Galectin Therapeutics' Income from Continuing Operations history runs 17 years deep, the most recent figure standing at 6029000.0 for Q1 2026.
- On a quarterly basis, Income from Continuing Operations rose 37.24% year-over-year to 6029000.0 in Q1 2026; TTM through Mar 2026 was 23712000.0, a 42.28% increase from a year earlier, with the FY2025 full-year figure at 115625000.0, up 12.69% from the prior year.
- Income from Continuing Operations eased to 6029000.0 in Q1 2026 per GALT's latest filing, from 5279000.0 in the prior quarter.
- Across five years, Income from Continuing Operations topped out at 5279000.0 in Q4 2025 and bottomed at 12480000.0 in Q2 2024.
- The 5-year median for Income from Continuing Operations is 9900000.0 (2022), against an average of 9279941.18.
- Across the five-year window, Income from Continuing Operations sank 59.76% in 2022 and surged 48.52% in 2025, its largest moves.
- Year by year, Income from Continuing Operations stood at 11486000.0 in 2022, then fell by 5.56% to 12125000.0 in 2023, then rose by 29.66% to 8529000.0 in 2024, then jumped by 38.11% to 5279000.0 in 2025, then dropped by 14.21% to 6029000.0 in 2026.
- Per Business Quant, the three latest GALT Income from Continuing Operations figures stand at 6029000.0 (Q1 2026), 5279000.0 (Q4 2025), and 5979000.0 (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -37.09 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 227.36 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -3.68 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | -26.94 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 362.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -453.82 Mn |
| 10 | Galectin Therapeutics | 227.21 Mn | 227.21 Mn | - | -6.03 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -6.03 Mn |
| Dec 31, 2025 | -5.28 Mn |
| Sep 30, 2025 | -5.98 Mn |
| Jun 30, 2025 | -6.43 Mn |
| Mar 31, 2025 | -9.61 Mn |
| Dec 31, 2024 | -8.53 Mn |
| Sep 30, 2024 | -10.47 Mn |
| Jun 30, 2024 | -12.48 Mn |
| Mar 31, 2024 | -10.62 Mn |
| Dec 31, 2023 | -12.13 Mn |
| Sep 30, 2023 | -9.94 Mn |
| Jun 30, 2023 | -9.60 Mn |
| Mar 31, 2023 | -10.76 Mn |
| Dec 31, 2022 | -11.49 Mn |
| Sep 30, 2022 | -8.37 Mn |
| Jun 30, 2022 | -9.90 Mn |
| Mar 31, 2022 | -10.16 Mn |
| Dec 31, 2021 | -7.27 Mn |
| Sep 30, 2021 | -8.35 Mn |
| Jun 30, 2021 | -8.28 Mn |